Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis

• DOI: 10.1128/aac.01956-19
• Publication Date: 2020-02-17T13:10:45Z
• Authors: K. F. Walsh; K. McAulay; M. H. Lee; S. C. Vilbrun; L. Mathurin; D. Jean Francois; M. Zimmerman; F. Kaya; N. Zhang; K. Saito; O. Ocheretina; R. Savic; V. Dartois; W. D. Johnson; J. W. Pape; C. Nathan; D. W. Fitzgerald

This study was conducted in treatment-naive adults with drug-susceptible pulmonary tuberculosis in Port-au-Prince, Haiti, to assess the safety, bactericidal activity, and pharmacokinetics of nitazoxanide (NTZ). This was a prospective phase II clinical trial in 30 adults with pulmonary tuberculosis. Twenty participants received 1 g of NTZ orally twice daily for 14 days. A control group of 10 participants received standard therapy over 14 days. The primary outcome was the change in time to culture positivity (TTP) in an automated liquid culture system.